Gilead Sciences (GILD) Updates on Study 102 for TAF on HIV-1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
Analyst Comments on Gilead Sciences (GILD) P-II TAF Study
March 5, 2013 3:19 PM ESTThis morning Gilead Sciences, Inc. (Nasdaq: GILD) announced detailed 24-week results from a Phase 2 study (Study 102) evaluating a once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection.
Commenting on the results, analyst at Wells Fargo said, "The... More
